Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET

Company Participants

Susan Pietropaolo - MD, Corporate Communications and IR
William Rice - Chairman, President and CEO
Rafael Bejar - SVP and CMO
Fletcher Payne - SVP, CFO, and CBO

Conference Call Participants

Joe Pantginis - H.C. Wainwright

Operator

Good afternoon. My name is Josh and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences' Conference Call for the First Quarter ended March 31st, 2024. At this time, all participants are in a listen only mode. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. As a reminder, this conference call may be recorded.

I would like to introduce Ms. Susan Pietropaolo. Please go ahead.

Susan Pietropaolo

Thank you, Josh. Good afternoon and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the first quarter ended March 31st, 2024.

Earlier today, Aptose issued a press release relating to these financial results. The news release as well as related SEC filings are accessible at Aptose's website.

Joining me on today's call are Dr. William Rice, Chairman, President and CEO; Dr. Rafael Bejar, Senior Vice President and Chief Medical Officer; and Mr. Fletcher Payne, Senior Vice President, Chief Financial Officer and Chief Business Officer.

Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of U.S. and Canadian Securities laws.

Forward-looking statements reflect Aptose's current expectations regarding future events. They are not guarantees of performance and it is possible that actual results and performance could differ materially these stated expectations. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievement to differ materially from those expressed.

To learn more about these risks and uncertainties, please read the risk factors set forth in Aptose's most recent quarterly report on Form 10-Q and SEC and SEDAR filings.

All forward-looking statements made during this call speak only as of the date they are made. Aptose undertakes no obligation to revise or update the statements to reflect events or circumstances after the date of this call, except as required by law. We encourage you to refer to today's press release and the 10-Q for additional information and disclosures regarding today's announcement.

I will now turn the call over to Dr. Rice.